Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective
Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective. // Journal of Cancer Policy. – URL: https://www.sciencedirect.com/science/article/pii/S2213538326000615?dgcid=rss_sd_all
Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective. Journal of Cancer Policy. https://www.sciencedirect.com/science/article/pii/S2213538326000615?dgcid=rss_sd_all
“Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective.” Journal of Cancer Policy.
@article{article117045,
title = {Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective},
journal = {Journal of Cancer Policy},
url = {https://www.sciencedirect.com/science/article/pii/S2213538326000615?dgcid=rss_sd_all}
}
ABSTRACT We investigate the long‐term impacts of participation in the Supplemental Nutrition Assistance Program (SNAP) before age 18 on adult mental health outcomes. Utilizing data from the Panel Study of Income Dynamics (PSID) spanning...
ABSTRACT Many major mental health conditions first emerge in childhood, when early intervention can produce both immediate and long‐term benefits. The United States has no federal paid sick leave (PSL) policy, but 18 states have...
ABSTRACT Value of information methods provide an approach to quantify the expected value of resolving uncertainty in a decision. It provides a quantitative basis to assess the expected value of clinical research projects and to...